UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 66

Sortiert nach

Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis

Respiratory research, 2022-12, Vol.23 (1), p.1-11, Article 330

2022

Volltextzugriff (PDF)

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

The Lancet (British edition), 2019-11, Vol.394 (10212), p.1940-1948

2019

Volltextzugriff (PDF)

Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients

Journal of aerosol medicine and pulmonary drug delivery, 2009-09, Vol.22 (3), p.263

2009

Volltextzugriff (PDF)

CFTR Modulators: Does One Dose Fit All?

Journal of personalized medicine, 2021-05, Vol.11 (6), p.458

2021

Volltextzugriff (PDF)

ECFS best practice guidelines: the 2018 revision

Journal of cystic fibrosis, 2018-03, Vol.17 (2), p.153-178

2018

Volltextzugriff (PDF)

Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough

Pediatric pulmonology, 2019-11, Vol.54 (11), p.1794-1800

2019

Volltextzugriff (PDF)

Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis

Science translational medicine, 2016-06, Vol.8 (344), p.344ra84

2016

Volltextzugriff (PDF)

Management of Individual Patient Expectations When Starting with Highly Effective CFTR Modulators

Journal of personalized medicine, 2021-08, Vol.11 (8), p.811

2021

Volltextzugriff (PDF)

Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation

Therapeutic advances in respiratory disease, 2022-01, Vol.16, p.17534666211070143-17534666211070143

2022

Volltextzugriff (PDF)

Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation

Journal of personalized medicine, 2021-04, Vol.11 (5), p.350

2021

Volltextzugriff (PDF)

Azithromycin maintenance therapy in patients with cystic fibrosis: A dose advice based on a review of pharmacokinetics, efficacy, and side effects

Pediatric pulmonology, 2012-07, Vol.47 (7), p.658-665

2012

Volltextzugriff (PDF)

Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in people with cystic fibrosis and healthy controls

Journal of cystic fibrosis, 2021-09, Vol.20 (5), p.e72-e76

2021

Volltextzugriff (PDF)

Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis

The European respiratory journal, 2016-02, Vol.47 (2), p.420-428

2016

Volltextzugriff (PDF)

Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer ®) for high powder doses

European journal of pharmaceutical sciences, 2006-06, Vol.28 (3), p.171-178

2006

Volltextzugriff (PDF)

Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations

Journal of cystic fibrosis, 2020-07, Vol.19 (4), p.614-619

2020

Volltextzugriff (PDF)

Elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study

Journal of cystic fibrosis, 2024-05, Vol.23 (3), p.549-553

2024

Volltextzugriff (PDF)

Targeted exhaled breath analysis for detection of Pseudomonas aeruginosa in cystic fibrosis patients

Journal of cystic fibrosis, 2022-01, Vol.21 (1), p.e28-e34

2022

Volltextzugriff (PDF)

The optimal approach to nutrition and cystic fibrosis: latest evidence and recommendations

Current opinion in pulmonary medicine, 2017-11, Vol.23 (6), p.556-561

2017

Volltextzugriff (PDF)

The effect of maintenance azithromycin on radiological features in patients with bronchiectasis - Analysis from the BAT randomized controlled trial

Respiratory medicine, 2022-02, Vol.192, p.106718-106718, Article 106718

2022

Volltextzugriff (PDF)

Radiological and long‐term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease

Pediatric pulmonology, 2023-08, Vol.58 (8), p.2317-2322

2023

Volltextzugriff (PDF)

The influence of exocrine pancreatic function on the exposure and pharmacokinetics of ivacaftor in people with cystic fibrosis

Journal of cystic fibrosis, 2023-05, Vol.22 (3), p.564-569

2023

Volltextzugriff (PDF)

Development and outcomes of a patient driven cystic fibrosis quality of care improvement project

Journal of cystic fibrosis, 2023-01, Vol.22 (1), p.172-178

2023

Volltextzugriff (PDF)

Body Weight and Body Mass Index in Patients with End-Stage Cystic Fibrosis Stabilize After the Start of Enteral Tube Feeding

Journal of the Academy of Nutrition and Dietetics, 2017-11, Vol.117 (11), p.1808-1815

2017

Volltextzugriff (PDF)

The prevalence of vascular and metabolic complications after lung transplant in people with cystic fibrosis in a Dutch cohort

Clinics (São Paulo, Brazil), 2023-01, Vol.78, p.100274-100274, Article 100274

2023

Volltextzugriff (PDF)

Prevalence of severe fatigue among adults with cystic fibrosis: A single center study

Journal of cystic fibrosis, 2018-05, Vol.17 (3), p.368-374

2018

Volltextzugriff (PDF)

1 – 25 von 66

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(62)

Publikationsform

Artikel
(66)

Sprache

Englisch
(66)
Portugiesisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(58)
Science & Technology
(58)
Cystic Fibrosis
(50)
Humans
(46)
Respiratory System
(33)
Male
(29)
Female
(28)
Adult
(26)
Cystic Fibrosis - Drug Therapy
(17)
Biological And Medical Sciences
(16)
Medical Sciences
(16)
Adolescent
(15)
Child
(12)
Cystic Fibrosis - Genetics
(12)
Mutation
(12)
Cystic Fibrosis Transmembrane Conductance Regulator - Genetics
(11)
Pharmacology. Drug Treatments
(11)
General & Internal Medicine
(10)
Cystic Fibrosis - Physiopathology
(9)
Anti-Bacterial Agents - Administration & Dosage
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients

CFTR Modulators: Does One Dose Fit All?

ECFS best practice guidelines: the 2018 revision

Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough

Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis

Management of Individual Patient Expectations When Starting with Highly Effective CFTR Modulators

Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation

Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation

Azithromycin maintenance therapy in patients with cystic fibrosis: A dose advice based on a review of pharmacokinetics, efficacy, and side effects

Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in people with cystic fibrosis and healthy controls

Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis

Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer ®) for high powder doses

Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations

Elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study

Targeted exhaled breath analysis for detection of Pseudomonas aeruginosa in cystic fibrosis patients

The optimal approach to nutrition and cystic fibrosis: latest evidence and recommendations

The effect of maintenance azithromycin on radiological features in patients with bronchiectasis - Analysis from the BAT randomized controlled trial

Radiological and long‐term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease

The influence of exocrine pancreatic function on the exposure and pharmacokinetics of ivacaftor in people with cystic fibrosis

Development and outcomes of a patient driven cystic fibrosis quality of care improvement project

Body Weight and Body Mass Index in Patients with End-Stage Cystic Fibrosis Stabilize After the Start of Enteral Tube Feeding

The prevalence of vascular and metabolic complications after lung transplant in people with cystic fibrosis in a Dutch cohort

Prevalence of severe fatigue among adults with cystic fibrosis: A single center study

Suchergebnisse filtern